EUVIMEDEUVIMED entdecken
Crossref

GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers

Shimin Ye, Dazhi Shi, Yuhang Ye, Jiahao Xie, Yali Yang, Weijun Wei, Hubing Wu

Molecular Pharmaceutics · 16.11.2026

DOI: 10.1021/acs.molpharmaceut.6c01072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 16.11.2026. Verfasst von Shimin Ye und 6 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glypican-3 (GPC3) is a particular biomarker for hepatocellular carcinoma (HCC). Theranostic strategies targeting GPC3 using single-domain antibodies (sdAbs), also known as nanobodies, show promising potential due to their high affinity and excellent tissue penetration. In this study, two novel GPC3-targeted sdAb-based PET probes were developed and tested in GPC3-positive HCC models. The GPC3-specific sdAb G6 and its albumin-binding domain (ABD)-fused variant ABDG6 were conjugated with NOTA and radiolabeled with [68Ga] to generate [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, whose binding kinetics, in short-term vitro stability, PET/CT being explore. G6 and ABDG6 showed high affinity for GPC3, with the binding affinity (KD values) of 0.62 nM for G6 and 0.43 nM for ABDG6. After radiolabeling, [68Ga]Ga-NOTA-G6 retained high affinity (KD = 5.4 nM) and demonstrated rapid blood clearance and GPC3-specific tumor accumulation, enabling relatively high-contrast imaging of GPC3 tumors at 60minutes post-injection (p.i.). The uptake of [68Ga]Ga-NOTA-G6 in tumors reached 2.40 ± 0.21 %ID/g, resulting in a high tumor-to-muscle ratio of 3.85 ± 1.32. This uptake could be competitively blocked to a low level (0.74 ± 0.17 %ID/g, P < 0.05). In contrast, [68Ga]Ga-NOTA-ABDG6 showed prolonged circulation and relatively reduced renal uptake. However, its affinity was relatively low (KD = 15.3 nM), and tumor retention did not improve over the 6 h observation period. Taken together, Two GPC3-targeted sdAb PET probes, [68Ga]Ga-NOTA-G6 and [68Ga]Ga-NOTA-ABDG6, were successfully developed. [68Ga]Ga-NOTA-G6 enabled high-contrast, high-specificity imaging of GPC3-positive HCC lesions. Although [68Ga]Ga-NOTA-ABDG6 achieved prolonged circulation, it did not produce enhanced tumor accumulation during the six-hour observation period. Further studies with longer-half-life radionuclides are needed for extended observation.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ye, S., Shi, D., Ye, Y., Xie, J., Yang, Y., Wei, W., & Wu, H. (2026). GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c01072

Vancouver

Ye S, Shi D, Ye Y, Xie J, Yang Y, Wei W, et al. GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c01072

BibTeX
@article{Ye2026,
  author = {Ye, Shimin and Shi, Dazhi and Ye, Yuhang and Xie, Jiahao and Yang, Yali and Wei, Weijun and Wu, Hubing},
  title = {GPC3-Targeted sdAb-PET Imaging of Hepatocellular Carcinoma with Single-Domain Antibody Tracers},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c01072}
}
Kostenlos starten →